A new use patent secured by Pediatric Neurologist and researcher Steven Rothman, MD has the potential to treat a problem that impacts a significant number of women. This patent explores a novel application for 4-aminopyridine (4-AP), a potassium channel blocker long used to improve neuronal function, by repurposing it as a topical medication that could be used to treat female sexual dysfunction (FSD). Studies suggest that FSD impacts between 38-63% of women. 

As populations age, sexual dysfunction increasingly becomes a central health concern. Although advances have provided several effective treatments for male sexual dysfunction, women have seen far fewer breakthroughs. One significant factor in FSD is diminished genital sensitivity, possibly due to the loss of sensory nerve excitability. Rothman’s idea targets this gap by hypothesizing that a topical formulation of 4-AP could restore or enhance nerve sensitivity, potentially increasing arousal and alleviating sexual dysfunction in women.

4-Aminopyridine has a well-established history in neurology.

“While engaged in laboratory research, I became interested in identifying novel uses for 4-AP; it’s been known for decades that blocking potassium channels can make nerves more excitable,” explains Rothman. “We and others used this property to create animal models for epilepsy. Clinicians also use 4-AP to enhance neuromuscular transmission in certain clinical conditions. I kept thinking, ‘There must be more we can do with this drug’.”

By applying 4-AP topically, Rothman’s approach aims to deliver higher local concentrations directly to the genital region while minimizing systemic exposure. This localized application should avoid some of the common side effects like seizures; offering a safer, targeted alternative for enhancing sensory nerve activity.

The journey ahead, though challenging, holds immense potential. Upstate is actively seeking industry partners to help complete the necessary preclinical toxicology studies and subsequent clinical trials.

“I’ve reached out to several companies; what we need now is a partner willing to invest in preclinical trials, or to work with the FDA on a limited study pathway, so that we can obtain preliminary data on efficacy,” he explained.

A collaboration could fast-track this innovative treatment into clinical practice, potentially offering women a new option for enhancing sexual function and their quality of life.

You can read more about Rothman’s patent here.

If you are interested in learning more about this patent, reach out to SUNY Research Foundation’s Mahfuz Miah; mahfuz.miah@rfsuny.org